Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Aloxi Prescribers for CINV: Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
December 1, 2008
Avastin Raises Risk of Clots: New News?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.
Donald FlemingNovember 26, 2008
It's always what's relative and seldom absolute
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Satistics are usually used to reveal dramatic differences Patients often misinterpret relative differences for absolute ones patients are willing to do a lot more to get any benefit in cancer outcome
Donald FlemingNovember 19, 2008
The rash and EGFR response can be helpful
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Many studies support EGFR response correlates with rash Many attempts to actually increase the incidence of rash Most patients will use the EGFR treatments despite the rash
Donald FlemingNovember 13, 2008
When being selective, targeted therapy will work
Analysis of: Tarceva successful as maintenance therapy | www.fiercebiotech.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Saturn trial attempted to focus on EGFR reative patients Saturn was positive as a maintenance therapy, while concurrent was not
Donald FlemingOctober 28, 2008
The TKI's are building on their success
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
TKI's have been establihed in a small number of refractory solid cancers With slow migration to other venues, we are seeing new applications
Donald FlemingOctober 28, 2008
Vaccine for prostate cancer fails
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent Cell Genesys vaccine trial for prostate cancer fails The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
Donald FlemingOctober 27, 2008
Hitting the target may reduce the use of targeted cancer drugs or not
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
We are facing an ever increasing expense of treating cancver The so called targeted drugs are the big price items The recent discovery of theses drugs have sometimes been out of order with understanding their activity
Donald FlemingOctober 24, 2008
The vaccine approach to cancer has yet to succeed
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Be cautious of vaccine approaches to cancer No cancer has had success with the use of vaccine therapy We are far from figuring out the reason for failure of vaccines to treat cancer
Donald FlemingOctober 20, 2008
We must hit the cancer target by genetics or whatever technique
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Targeted therapy for cancer is the new trend Targeted therapy will allow the use of more expensive drugs to be more practical We need to focus on hitting a target more than ever
Donald FlemingOctober 20, 2008
Government Run Cancer care
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
There has been distubing trends in nationalized health care in regrds to cancer care Recently the UK made an absolutely shocking decision on renal cancer therapy, as it has in other cancers in the past Hopefully through advances in predicting cancer therapy outcomes via microarray etc. we can...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 168

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637